相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma
Ingrid Alexandre et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Sunitinib-Induced Hemoglobin Changes Are Related to the Dosing Schedule
Astrid A. M. van der Veldt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib
Doru T. Alexandrescu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways
Kevin Wei et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
Ronald M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis
R. M. Bukowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis
Betty Y. Y. Tam et al.
NATURE MEDICINE (2006)
Sunitinib in patients with metastatic renal cell carcinoma
Robert J. Motzer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia
JL Canon et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Role of c-Kit and erythropoietin receptor in erythropoiesis
V Munugalavadla et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from rive randomized clinical trials
D Cella et al.
ANNALS OF ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer
W Kim et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2003)
Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy
S Richard et al.
BLOOD (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
